CIPLA Stock View

Cipla Ltd
stock-view-header

₹ 1,186.15

icon -1.90 | -0.16
Market Cap ₹( Cr.)
957,609.10
Proj. P/E (x)
26.83
Proj. P/BV (x)
3.62
Proj. ROE (%)
14.41
Proj EV / EBITDA (x)
--
Proj. Revenue ( Cr.)
254,056.01

Stock View

BUY

Last Updated On.
01-Oct-2023
 

The average score for Cipla Ltd stands at 8 against 9, three months back.

Cipla Limited is an India-based company, which is primarily engaged in the business of pharmaceuticals. The Company operates through two segments: Pharmaceuticals and New ventures. The Pharmaceuticals segment is engaged in developing, manufacturing, selling, and distributing generic or branded generic medicines, as well as Active Pharmaceutical Ingredients (API). The New ventures segment includes the operations of the Company, a consumer healthcare, Biosimilars and specialty business. The Company's product portfolio spans complex generics, as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective and central nervous system (CNS). The Company's geographical segments include India, the United States, South Africa, and Rest of the World. The Company has its network of manufacturing, trading and other incidental operations in India and International markets. The Company has approximately 47 manufacturing sites.

Disclaimer : All estimates (1 year forward) are based on Consensus View provided by Refinitiv.


Technical Data

50 DMA(₹)
1,204.16
100 DMA(₹)
1,092.45
200 DMA(₹)
1,037.84
52 Weeks Range
852.00     1,277.55

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required